Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Tom Latham who wrote (30038)	12/17/1998 1:23:00 PM
From: Captain Ed	Respond to of 119973

MCHM...Huge news just out...maybe bigger than Viagra!! News attached Macrochem Corporation Announces Preliminary Phase IIB Results With Topiglan Gel PR Newswire - December 17, 1998 12:57 LEXINGTON, Mass., Dec. 17 /PRNewswire/ -- MacroChem Corporation (NASDAQ: MCHM) announced today a preliminary review of a Phase IIB study of its topical gel, Topiglan, a proprietary topical formulation of alprostadil, in the treatment of erectile dysfunction. The study was carried out by Dr. Irwin Goldstein of the Department of Urology at Boston University Medical Center. The study was double-blind (i.e., neither the patient nor the investigator nor MacroChem knew any patient's treatment), randomized, placebo-controlled (i.e., assignment to the Topiglan or placebo group was by chance, with half the subjects receiving 0.25 ml 1% alprostadil in a SEPA -formulated gel, and the other half a SEPA-formulated gel without alprostadil) in an office setting with visual and tactile stimulation. Sixty patients with documented erectile dysfunction, were treated with either Topiglan or placebo, applied topically to the head of the penis. Many of the patients had previously failed to respond to available therapies, including Viagra, MUSE and surgical revascularization. Topiglan application was associated with statistically greater penile rigidity and tumescence (p=0.033) compared to placebo, as assessed by the physician. This was confirmed by the patient's assessment in which Topiglan was also rated as significantly better than placebo (p=0.003). In fact, six times more patients stated that the erection attained following Topiglan application was sufficient for vaginal intercourse compared to placebo-treated patients (p=0.005). Treatment was accompanied by transient, minor to mild symptoms of localized warmth, occasionally minor to mild burning or tingling in some patients, with no difference observed between Topiglan and placebo treatments. There were no significant changes in vital signs in any patient in either group. Dr. Goldstein commented: "These data demonstrate that Topiglan applied topically to the glans of the penis is effective to increase penile rigidity in patients with significant erectile dysfunction, with the result that an increased number of these individuals attained erections judged adequate for vaginal penetration." MacroChem develops and licenses products and technology for the transdermal delivery of agents for pharmaceutical and cosmetic applications. The Company's patented technology, SEPA, an absorption enhancer for transdermal delivery, can effectively increase the passage of therapeutic agents through the skin, offering significant advantages over other methods of delivery. MacroChem's technology is focused on four major therapeutic areas: sexual dysfunction, pain management, hormone replacement, and dermatological conditions. To the extent that this press release discusses matters relating to the development of future products, these are forward-looking statements and are subject to various risk factors that could cause actual results to differ materially from those expressed in the forward-looking statements. The relevant risk factors are set forth in MacroChem's annual report on Form 10-K as filed with the SEC and include, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products. Visit our web site at: macrochem.com or mchm.com SOURCE MacroChem Corporation /CONTACT: Michael Kaiser of MacroChem Corporation, 781-862-4003/ /Web site: macrochem.com /Web site: mchm.com Ed

To: Tom Latham who wrote (30038)	12/17/1998 1:23:00 PM
From: QKAnd	Respond to of 119973

Rumors of buy rec heard for IMMU with possible breast cancer application in near future. Holding through holidays.

To: Tom Latham who wrote (30038)	12/17/1998 1:23:00 PM
From: jackal 44	Respond to of 119973

Maybe tomorrow, HOTT news pretty bad IMO Hot Topic Inc. Announces Early Holiday Sales Results BusinessWire, Thursday, December 17, 1998 at 10:17 POMONA, Calif.--(BUSINESS WIRE)--Dec. 17, 1998--Hot Topic Inc. (Nasdaq/NM:HOTT) Thursday announced that comparable store net sales to-date for the fourth quarter (the first six weeks and three days of the quarter through Tuesday, Dec. 15, 1998) decreased 10.2 percent, or approximately $12,000 per store, compared with the same period last year. Ninety-eight of its 157 stores are in the comparable store base. The sales pattern has been similar for the non-comparable stores. Orv Madden, president and chief executive officer, said: "Early sales in this holiday season have been disappointing. The sales trend has been nationwide in our stores and generally across all merchandise categories in new, as well as comp, stores. "We believe that the primary reasons for the lower sales are more related to the teen retail sector than to our merchandise content. We believe that mall traffic has been lighter than normal throughout the country, possibly the result of unseasonably warm weather." Madden continued: "Markdowns and sales promotions to-date in the fourth quarter have been moderately greater than last year. The next two weeks have historically been the most important sales days of the quarter, when teens are out of school. "Certain of our products, such as gift certificates and customer gift registries, are running ahead of last year. Although these products could have a positive sales impact later in the quarter, we are unable to project a change in the sales trends at this time." The company expects to release sales for the nine-week period ending Jan. 2, 1999, during the week of Jan. 4, 1999. Hot Topic is a mall-based specialty retailer of music-licensed and music-influenced apparel, accessories and gift items for young men and women principally between the ages of 12 and 22. The company currently operates 157 stores in 38 states in the United States.